TRXB
NASDAQTRex Bio Inc.
$13.77-0.32 (-2.31%)
TRex Bio Inc. (TRXB) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for TRXB, including 4 analyst ratings, 2 SEC filings and 1 earnings update. The most recent was published Nov 13, 2026.
Price$13.77-0.32 (-2.31%)
03:00 PM08:45 PM
News · 26 weeks7+100%
2026-05-172026-11-08
Mix790d
- Analyst4(57%)
- SEC Filings2(29%)
- Earnings1(14%)
Activity · 52 weeks73 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
7 items- SECSEC Form 10-Q filed by TRex Bio Inc.10-Q - TRex Bio, Inc. (0002139097) (Filer)
- SECTRex Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TRex Bio, Inc. (0002139097) (Filer)
- PRTRexBio Reports Third Quarter 2026 Financial Results and Recent Business HighlightsPositive Phase 1a results for TRB-061 support proof of mechanism, with topline Phase 1b data in atopic dermatitis expected in mid-2027TRB-071 advancing through IND-enabling studies, with Phase 1 trial initiation expected in the first half of 2027Completed a $133.5 million initial public offering in October 2026, extending expected cash runway into the second half of 2029 SOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. ("TRexBio") (NASDAQ:TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today reported financial results for the third quarter ended September 30, 2026, an
- ANALYSTCantor Fitzgerald initiated coverage on TRex Bio, Inc.Cantor Fitzgerald initiated coverage of TRex Bio, Inc. with a rating of Overweight
- ANALYSTStifel initiated coverage on TRex Bio, Inc. with a new price targetStifel initiated coverage of TRex Bio, Inc. with a rating of Buy and set a new price target of $39.00
- ANALYSTAnalyst initiated coverage on TRex Bio, Inc. with a new price targetAnalyst initiated coverage of TRex Bio, Inc. with a rating of Overweight and set a new price target of $20.00
- ANALYSTWedbush initiated coverage on TRex Bio, Inc. with a new price targetWedbush initiated coverage of TRex Bio, Inc. with a rating of Outperform and set a new price target of $30.00
TRXB FAQ
8 questionsWhat does TRex Bio Inc. do?
TRexBio is a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio's Deep Biology Platform decodes Treg functionality in human tissue, mapping key drivers of immune dysregulation and uncovering novel targets and insights that inform drug discovery and translational efforts. This platform has generated multiple therapeutic development candidates across TRexBio's wholly...What is the latest news on TRXB?
In the last 30 days Quantisnow tracked 7 wire items for TRXB: 4 analyst ratings, 2 SEC filings and 1 earnings update. The most recent was published on November 13, 2026.Where does TRXB stock trade?
TRex Bio Inc. (TRXB) is listed on NASDAQ.What sector and industry is TRXB in?
TRex Bio Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did TRex Bio Inc. go public?
TRex Bio Inc. (TRXB) completed its IPO in 2026.What are analysts saying about TRXB?
TRex Bio Inc. has had 4 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight on 2026-11-03. Recent price targets range from $20.00 to $39.00.What companies are similar to TRXB?
Notable peers in the same industry include MRNA (Moderna Inc.), AMGN (Amgen Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare TRXB side-by-side with any of them on Quantisnow.How can I track TRXB on Quantisnow?
Quantisnow aggregates TRex Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TRXB to receive live email and push alerts on every new disclosure.